GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is conducting a Phase 2 study titled ‘A Phase ...

In a report released today, Benjamin Jackson CFA from Jefferies upgraded GlaxoSmithKline to a Buy, with a price target of £20.00. The company’s shares opened today at p1,631.50. Take advantage of ...

GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 m, reinforcing ...

Part of a pharmaceutical factory which opened more than 75 years ago will be demolished. GSK plc (formerly GlaxoSmithKline) ended its Cumbria operations earlier this year at its Ulverston site, after ...

A pharmaceutical factory which ceased production earlier this year has been bought by Britain's biggest defence firm. BAE ...

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

CNW/ - Dalhousie University, in collaboration with Nova Scotia Health's INSPIRED COPD Outreach Program, the Nova Scotia ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...